CXCR3 Antibody Halves Brain T-Cell Infiltration, Preserves 40% More Tissue in Tauopathy Mice

In the Neuron study, Holtzman’s group dosed tauopathy mice with anti-CXCR3 for several months. T-cell numbers inside the brain fell approximately 50%. Treated animals retained roughly 40% more tissue volume in the hippocampus and entorhinal cortex and scored higher on object-recognition memory tests than untreated littermates, even though total tau burden and tangle density remained statistically identical.

The approach targets peripheral chemokine signaling rather than brain tau itself. It extends the lab’s 2023 Nature finding that T cells drive neurodegeneration in tau models and the subsequent Nature Neuroscience report tracing CXCL10 production to lymph nodes. Unlike lecanemab or donanemab, which clear amyloid but do not stop neuronal loss in primary tauopathies, CXCR3 blockade acts downstream of tangle formation and avoids blood-brain-barrier penetration.

Human translation will require safety data on systemic CXCR3 inhibition and confirmation that the same T-cell axis operates in sporadic Alzheimer’s and frontotemporal dementia. Phase-1 trials could begin within three years if toxicology clears.